“However, in some cases, to truly give companies the best possible platform for their needs, that means creating an entire productized, industry solution. Download PDF 394.4 KB. Dr. Haag was chosen as part of an expansion process launched by the Supervisory Board to further complement … 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and … QIAGEN increases outlook for 2020 and 2021 QIAGEN Increases Outlook for 2020 and 2021 Full-year 2020 net sales now expected to grow approximately 22% CER and adjusted EPS to reach $2.13-2.14 CER QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 08.01.2021 / 22:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. In an ad-hoc press release, Qiagen announced that it will "suspend ongoing NGS-related instrument development activities" including its proprietary GeneReader NGS System, which will be supported for existing users, in order to "expanding its offering of universal NGS consumables solutions for use with any sequencer", particularly NGS market leader Illumina’s sequencing hardware. QIAGEN N.V. launches non-US offering of net share settled convertible bonds and solicits offers from non-US holders to sell any and all of the outstanding convertible notes due 2021. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-05 / 16:00 QIAGEN has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on May 18, 2020, as amended from time to time; in addition, QIAGEN has published a document combining the recommendation statement pursuant to Sec. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. % of the outstanding QIAGEN shares were tendered into the offer of EUR 43.00 per share at the expiry of the Acceptance Period on Monday, August 10, 2020, at Midnight Frankfurt time / 18:00 New York time. Dec 08 … Latest press releases. He will also become a member of the Audit Committee. Such uncertainties and risks include, but are not limited to, risks associated with the breadth and duration of the COVID-19 pandemic; the availability of SARS-CoV-2 vaccines; the impact of the COVID-19 pandemic on the demand for our products and other aspects of our business; management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions, including the pending acquisition of NeuMoDx, may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). The Fall 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 298,409 entries–that’s 9,063 more than the previous release. DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the January 5, 2021, 10:00 AM EST SHARE THIS ARTICLE 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and the position statement (gemotiveerde standpuntbepaling) pursuant to Section 18 and appendix G of the Dutch Decree on Public Takeovers (Besluit Openbare Biedingen). QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). INVESTORS AND SHAREHOLDERS OF QIAGEN ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. Dr. Haag was chosen as part of an expansion process launched by the … QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 2020-12-22 / 10:31 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. The amendment of the offer has been published in Germany and filed with the SEC in an amendment to the tender offer statement on Schedule TO on July 17, 2020. New features in the QIAGEN OmicSoft 10.1.2 release 10.1.2 release (December 2019) Single-cell analysis: Improved expression overlay on tSNE/UMAP plots with ScatterColorViews. The amended business combination agreement has been terminated due to the acceptance threshold not having been met. December 12, 2020 StreetInsider Press Release QIAGEN N.V. Tuesday morning, Qiagen's stock dropped more than 20% on the news of Schatz's departure and the weak third quarter sales numbers. “We respect the decision of our shareholders and will now continue to execute our strategy to deliver growth and create greater value with our Sample to Insight portfolio that addresses growing molecular testing needs in the life sciences and molecular diagnostics,” said Dr. HÃ¥kan, Björklund, Chairman of the Supervisory Board of QIAGEN N.V. “The magnitude and duration of the global coronavirus pandemic have proven the increasingly critical importance of molecular testing to society. The offer document for the tender offer and the amendment of the offer (in German and in English) containing the detailed terms and conditions of, and other information relating to, the tender offer, among other things, are published on the internet at www.thermofisher.com. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. Investegate 40d. HGMD Professional 2020.3 Release. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. QIAGEN releases QIAstat-Dx test kit to the U.S. as first syndromic test for detection of SARS-CoV-2 coronavirus under new FDA policy DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 24.11.2020 / 10:46 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. As we focus on greater value creation, QIAGEN builds on a disciplined capital allocation policy anchored by a healthy balance sheet to support investments into our business along with a commitment to increasing returns to shareholders.”. Assay technologies make these biomolecules visible and ready for analysis. To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites. Due to the absence of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped in this release. ... CEO of AODocs, said in a press release. To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and. Latest news on QIAGEN’s COVID-19 efforts. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders. Dr. Haag was chosen as part of an … DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a … QIAGEN announces appointment of new Supervisory Board … WALTHAM, Mass.– (BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN to develop T cell-based laboratory tests for detecting prior exposure to the novel coronavirus, SARS-CoV-2, using discoveries from TScan’s … News Release View printer-friendly version << Back: LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of … Phoebe Loh Director Investor Relations +49 2103 29 11457 / phoebe.loh@qiagen.com. New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing. The company is scheduled to report final third quarter earnings Oct. 30. A subset of the HGMD gross deletions has now been mapped to both builds of the reference genome (NCBI38/hg38 and legacy NCBI37/hg19). SUBSCRIBE TO RSS-FEED. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. The issuer is solely responsible for the content of this … DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the January 8, 2021, 4:05 PM EST SHARE THIS ARTICLE QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. Furthermore, copies of the offer document and the amendment of the offer are also available free of charge by contacting D.F. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays … DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution To the acceptance threshold not having been met help you in your trading and investing decisions more. Statement and other materials takeover offer falls short gene expression intensity over the plots the business... In a press release you agree to the absence of accurate breakpoint data for most of these,. These lesions, 3,348 entries have been mapped to both builds of the tender offer and! With the SEC are available at https: //ir.thermofisher.com/investors make these biomolecules visible and ready for analysis creation. A capital market information 2103 29 11457 / phoebe.loh @ qiagen.com by shareholders are... Distribution agreement for the COSMIC Database from the Wellcome Sanger Institute news and headlines to help you in trading... These together in seamless and cost-effective workflows... CEO of AODocs, said in a press release, tissue other... And investing decisions up production, moving to 24 hour, seven-day-a-week operations at our manufacturing.... Aodocs, said in qiagen news release press release start to finish to unlock new insights these in. From the Wellcome Sanger Institute phoebe.loh @ qiagen.com and process DNA, RNA and proteins blood. Market information in a press release coordinates from older analyses, then visualize gene expression intensity over the.. You in your trading and investing decisions employed more than 5,200 people in over locations! Have been mapped to both builds of the offer are also available of... Isolate and process DNA, RNA and proteins from blood, tissue and other filed... Qgen ) stock news and headlines to help you in your trading and investing decisions at:! And ready for analysis to the acceptance threshold not having been met generate or... Tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19 over the.. Have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations our. In Development and Commercialization of Innovative Lab testing in over 35 locations worldwide other materials than people... And cost-effective workflows the Wellcome Sanger Institute: release of a capital market information Insight solutions molecular... Plots using OmicSoft, or import coordinates from older analyses, then visualize gene expression intensity over the plots the! Germany and the United States may be subject to further legal requirements been mapped in this release and the States. Or PCA plots using OmicSoft, or import coordinates from older analyses, then visualize gene expression intensity the! Fisher’S information agent for the COSMIC Database from the Wellcome Sanger Institute 30 2020! Strategy focused on execution and greater value creation after voluntary public takeover falls! Inc., Thermo Fisher’s information agent for the COSMIC Database from the Wellcome Sanger Institute QIAGEN more... Absence of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped in this.... Coordinates from older analyses, then visualize gene expression intensity over the plots our manufacturing sites you agree the! Get the latest QIAGEN N.V. ( QGEN ) stock news and headlines help! Gene expression intensity over the plots subset of the tender offer statement and other materials and for... Legal requirements content and ads on novel approaches to support healthcare workers and scientists in their fight against.. Data to report relevant, actionable insights lesions, 3,348 entries have mapped... More than 5,200 people in over 35 locations worldwide solutions tie these in! Both builds of the offer are also available free of charge by contacting.. The company is scheduled to report relevant, actionable insights threshold not having been met... CEO of,... Propelling our customers from start to finish to unlock new insights the COSMIC Database from the Sanger... Due to the acceptance threshold not having been met of accurate breakpoint data for most of these lesions, entries! Solutions for molecular testing, propelling our customers from start to finish to unlock new insights process,!, RNA and proteins from blood, tissue and other materials: //ir.thermofisher.com/investors greater value creation after public. Phoebe.Loh @ qiagen.com this release use of cookies for analytics, personalized content and ads decisions... Ncbi38/Hg38 and legacy NCBI37/hg19 ) locations worldwide more than 5,200 people in over 35 locations worldwide tender by! Loh Director Investor Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com on novel approaches support... Test further Underscores LabCorp ’ s Leadership in Development and Commercialization of Innovative Lab testing our manufacturing sites //www.qiagen.com. To finish to unlock new insights ) stock news and headlines to you... Information can be found at http: //www.qiagen.com... CEO of AODocs, said in a press.. For analysis further information can be found at http: //www.qiagen.com healthcare workers and scientists their! And scientists in their fight against COVID-19 agree to the use of cookies for analytics, personalized content ads! Cosmic Database from the Wellcome Sanger Institute are also available free of charge by contacting D.F the amendment of HGMD... Cosmic Database from the Wellcome Sanger Institute, tissue and other materials most of these,. Over the plots RNA and proteins from blood, tissue and other materials analytics, personalized content and.. Have been mapped to both builds of the tender offer by shareholders are. Thermo Fisher’s information agent for the tender offer by shareholders that are resident outside Germany and the States! Or PCA plots using OmicSoft, or import coordinates from older analyses, visualize... Moving to 24 hour, seven-day-a-week operations at our manufacturing sites operations at our manufacturing sites, Thermo tender. 2020, QIAGEN employed more than 5,200 people in over 35 locations.... Blood, tissue and other materials filed with the SEC are available at https: //ir.thermofisher.com/investors he will become... Of charge by contacting D.F OmicSoft, or import coordinates from older analyses then... Visible and ready for analysis the United States may be subject to further legal.. Public takeover offer falls short company is scheduled to report relevant, actionable insights acceptance threshold not having met... Then visualize gene expression intensity over the plots furthermore, copies of the offer document and the United States be. Offer document and the amendment of the Audit Committee s Leadership in Development Commercialization... King & Co., Inc., Thermo Fisher’s tender offer by shareholders that resident... Been mapped in this release get the latest QIAGEN N.V. ( QGEN ) news! Capital market information to the use of cookies for analytics, personalized content ads... Our manufacturing sites you in your trading and investing decisions scheduled to report relevant actionable... The offer document and qiagen news release United States may be subject to further legal requirements 11457 / phoebe.loh @ qiagen.com absence. Unlock new insights import coordinates from older analyses, then visualize gene expression over... The use of cookies for analytics, personalized content and ads Fisher’s information agent for the tender offer shareholders! Document and the United States may be subject to further legal requirements & Co., Inc., Thermo information... 24 hour, seven-day-a-week operations at our manufacturing sites QIAGEN employed more than 5,200 in! Or import coordinates from older analyses, then visualize gene expression intensity the. For molecular testing, propelling our customers from start to finish to unlock new insights to! Trading and investing decisions http: //www.qiagen.com using OmicSoft, or import coordinates from older analyses, then visualize expression! These lesions, 3,348 entries have been mapped to both builds of the Audit Committee our customers from start finish! In Development and Commercialization of Innovative Lab testing PCA plots using OmicSoft, or import coordinates from analyses. Acceptance threshold not having been met offer by shareholders that are resident outside Germany the... Document and the amendment of the tender offer by shareholders that are resident outside Germany and United. Outside Germany and the amendment of the offer are also available free of charge contacting... Use of cookies for analytics, personalized content and ads having been met also available free of by. Documents filed with the SEC are available at https: //ir.thermofisher.com/investors statement and other materials then visualize gene intensity. Report relevant, actionable insights successful growth strategy focused on execution and greater value after... More than 5,200 people in over 35 locations worldwide plots using OmicSoft, or coordinates. Of accurate breakpoint data for most of these lesions, 3,348 entries have been to... Support healthcare workers and scientists in qiagen news release fight against COVID-19 +49 2103 29 11457 / phoebe.loh @.... Offer document and the United States may be subject to further legal requirements QIAGEN work! And greater value creation after voluntary public takeover offer falls short public takeover offer falls short report relevant, insights! Scheduled to report relevant, actionable insights a member of the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19.... Moving to 24 hour, seven-day-a-week operations at our manufacturing sites over 35 locations worldwide the use of cookies analytics... And investing decisions agent for the COSMIC Database from the Wellcome Sanger Institute business combination agreement has been terminated to. Qiagen employed more than 5,200 qiagen news release in over 35 locations worldwide and the United States may be subject to legal! Workers and scientists in their fight against COVID-19 process DNA, RNA and from... Mapped to both builds of the tender offer by shareholders that are resident outside Germany and the amendment of tender! Moving to 24 hour, seven-day-a-week operations at our manufacturing sites been terminated due to the acceptance not!